Company news
Nanobiotix SA news in 2026
Nanobiotix SA's news releases, calls and decks from 2026, newest first.
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
October 23, 2026
Voting Rights and Shares Capital of the Company
October 19, 2026
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
October 1, 2026
NANOBIOTIX annonce la nomination d’Arnd Christ au poste de directeur financier
September 30, 2026
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
September 24, 2026
NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
September 23, 2026
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
September 14, 2026
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
September 13, 2026
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
September 8, 2026
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
August 24, 2026
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
July 29, 2026
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
June 2, 2026
Nanobiotix Joins the Euronext Tech Leaders Index
June 2, 2026
NANOBIOTIX Announces Closing of Global Offering
May 26, 2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
May 21, 2026
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
May 21, 2026
Nanobiotix Announces Launch of Global Follow-On Offering
May 20, 2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 17, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 4, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
Voting Rights and Shares Capital of the Company
April 7, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
March 31, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
March 26, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
March 25, 2026
NANOBIOTIX to Participate in Investor Conferences in March
February 25, 2026
Calls in 2026
Decks in 2026
- Q4 2025 Earnings Presentation
Earnings · 50 slides · Apr 1, 2026